Summit Therapeutics reported a wider-than-expected loss and disclosed a 'going concern risk' due to insufficient cash to fund operations for the next year, despite raising over $300 million recently. The company is cutting costs and has $690.7 million in cash and investments. Its lead lung cancer drug, ivonescimab, showed positive Phase 3 data with improved survival trends, and the company has submitted this data to the FDA for approval. Analyst Jefferies lowered the price target but still sees potential upside for the stock.
Guggenheim has reiterated its Buy rating on Summit Therapeutics despite lowering the price target slightly to $38 from $40, indicating confidence in the stock's upside from its current price of $14.98. The positive outlook follows strong Q2 2026 earn...
Summit Therapeutics has been upgraded from 'Hold' to 'Buy' following the FDA's acceptance of its Biologics License Application (BLA) for ivonescimab combined with chemotherapy to treat EGFR-mutant non-small cell lung cancer (NSCLC). The company's Pha...
